Clinical Data "completes transformation" as it awaits FDA decision on new antidepressant
This article was originally published in Scrip
Executive Summary
Clinical Data of the US says it has completed its "transformation into a pharmaceutical company" following the sale of its genetic and pharmacogenetic testing and biomarker development business to Transgenomic for $15.5 million.